Oncology Focus : CAR-T and CAR-NK therapies represent ~30% of all cell and gene trials, with a strong focus on solid and hematological malignancies. Significant attention on gastrointestinal tract and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback